Search
Azelaic acid
go.drugbank.com/drugs/DB00548ApprovedInvestigationalAzelaic acid is effective against a number of skin conditions, such as mild to moderate acne, when applied topically in a cream formulation of 20%. … It is also produced by _Malassezia furfur_, also known as _Pityrosporum ovale_, which is a species of fungus that is normally found on human skin.
Mixtures: Azelaic Acid 15% / Niacinamide 4%, 2% Salicylic Acid FACIAL CLEANSERSynonyms: n-nonanedioic acidBromocriptine
go.drugbank.com/drugs/DB01200ApprovedInvestigationalWithdrawnBromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. … [L43942,L43947] It continues to be used for the indications mentioned above.
Categories: Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-1 Receptor AntagonistsSynonyms: 2-bromo-α-ergokryptin, 2-bromo-α-ergocryptineAtogepant
go.drugbank.com/drugs/DB16098ApprovedInvestigationalIt was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021. … [L44642] It also received approval for preventive treatment of adult migraine by the EMA in August 2023.
Categories: MATE 1 Inhibitors, Heterocyclic Compounds, 1-RingProducts: AQUIPTA® 10 MG, AQUIPTA® 60 MGManganese gluconate
go.drugbank.com/drugs/DB11141ApprovedManganese gluconate is a direct ingredient in food substances as a nutrient supplement. In pharmaceutical preparations it is used as a [DB06757] supplement. … It is typically obtained by reacting manganese carbonate with gluconic acid in aqueous medium and then crystallizing the product to form a slightly pink powder.
Mixtures: Cal-mag Plus K, Mn and Zn Caplets, E 400iu W Selenium 100mcgSynonyms: Manganese D-gluconatePadimate O
go.drugbank.com/drugs/DB11570ApprovedIt is a structurally-related compound to [DB02362] that absorbs UV-B rays to prevent photodamage. … Padimate O is an active sunscreen agent in cosmetics and over-the-counter sunscreen drug products in concentrations up to 8%, as regulated by the FDA [L2153].
Synonyms: Padimate O, Padimate-OMixtures: Kiss My Face Everyday Moisturizer SPF 15-lot, Kiss My Face SPF 18 Lip BalmSpiramycin
go.drugbank.com/drugs/DB06145ApprovedInvestigationalWithdrawnSpiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens that has been available in oral formulations since 1955, and parenteral formulations since 1987. … Spiramycin is a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types
Mixtures: METİRASİN 1,5 MIU/250 MG FİLM KAPLI TABLET, 10 ADET, METİRASİN 1,5 MIU/250 MG FILM TABLET, 14 ADETCategories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 Enzyme InhibitorsSelinexor
go.drugbank.com/drugs/DB11942ApprovedInvestigational[L7123] Selinexor was also granted accelerated approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have gone through at least 2 lines of … Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: Nexpovio 20 mg Film Kaplı Tablet, 8 TABLET, Nexpovio 20 mg Film Kaplı Tablet, 12 TABLETDelafloxacin
go.drugbank.com/drugs/DB11943ApprovedInvestigationalIt was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections. … Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections,
Categories: 4-Quinolones, Cytochrome P-450 CYP2C9 InducersProducts: Quofenix 450 mg Tablet, 10 ADET, Quofenix 300 mg İnfüzyonluk Çözelti Hazırlamada Kullanılacak Konsantre İçin Toz, 10 ADETSelumetinib
go.drugbank.com/drugs/DB11689ApprovedInvestigationalNF-1 is considered rare, with an estimated incidence of 1/3000 individuals. … [A193611] "The novel MEK 1/2 inhibitor, selumetinib, was initially approved solely for the treatment of pediatric patients with Neurofibromatosis type 1 (NF-1) and symptomatic, inoperable plexiform
Categories: Mitogen-Activated Protein Kinase Kinase 1 Inhibitors, P-glycoprotein substratesProducts: Koselugo Hard Capsules 10 mg, Koselugo Hard Capsules 25 mg